Reduction or prevention of sensitization to drugs
August 3, 2010. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 3598122 3598123 Iontophoresis apparatus for applying local anesthetics Epidermal iontophoresis device Non-invasive chemical species delivery apparatus and method Monitoring and stimulation electrode Therapeutic system for administering drugs to the skin Dissolution controlled active agent dispenser Iontophoretic treatment apparatus Dosage for coadministering drug and percutaneous absorption enhancer InventorsApplicationNo. 562788 filed on 08/03/1990US Classes:424/449, Transdermal or percutaneous424/448Pressure sensitive adhesive meansExaminersPrimary: Page, Thurman K.Assistant: Phelan, D. Gabrielle Attorney, Agent or FirmInternational ClassA61F 013/00AbstractThe present invention is directed to a method of reducing or preventing skin sensitization by inhibiting the immunological processing of a sensitizing drug as an antigen. The drug is sensitizing to humans, i.e., the drug is susceptible to inducing skin or mucosa sensitization in a human when the drug is transdermally administered to the human at a therapeutically effective rate. Skin sensitization reduction or prevention is induced by coadministering to the skin or mucosa of the human:(a) a therapeutically effective amount of a sensitizing drug, at a therapeutically effective rate over a predetermined period of time; and(b) an antigen processing-inhibiting agent in an amount effective to inhibit the antigen processing of the drug.The system of the invention comprises a matrix adapted to be placed in sensitizing drug and antigen processing-inhibiting agent transmitting relation to the selected skin or mucosa site. The matrix contains sufficient amounts of the drug and the agent to continuously coadminister to the skin or mucosa site the drug, at a therapeutically effective rate and over a predetermined delivery period, and the antigen processing-inhibiting agent, at a rate and for a period of time sufficient to inhibit the processing of the drug as an antigen.Other References
| |
